Your browser is no longer supported. Please, upgrade your browser.
GILD Gilead Sciences, Inc. monthly Stock Chart
Gilead Sciences, Inc.
IndexS&P 500 P/E30.38 EPS (ttm)2.11 Insider Own0.54% Shs Outstand1.28B Perf Week-0.25%
Market Cap82.05B Forward P/E9.18 EPS next Y6.96 Insider Trans-0.97% Shs Float1.26B Perf Month-4.35%
Income2.71B PEG17.80 EPS next Q1.67 Inst Own82.80% Short Float1.69% Perf Quarter-2.92%
Sales22.37B P/S3.67 EPS this Y-45.60% Inst Trans-0.05% Short Ratio3.02 Perf Half Y-4.05%
Book/sh16.26 P/B3.93 EPS next Y-0.67% ROA4.30% Target Price76.92 Perf Year-6.32%
Cash/sh17.81 P/C3.59 EPS next 5Y1.71% ROE12.40% 52W Range60.89 - 70.50 Perf YTD-1.60%
Dividend2.52 P/FCF16.81 EPS past 5Y18.10% ROI12.00% 52W High-9.30% Beta1.21
Dividend %3.94% Quick Ratio2.90 Sales past 5Y14.60% Gross Margin79.60% 52W Low5.01% ATR1.04
Employees11000 Current Ratio3.00 Sales Q/Q0.10% Oper. Margin19.40% RSI (14)43.72 Volatility1.63% 1.48%
OptionableYes Debt/Eq1.19 EPS Q/Q-157.30% Profit Margin12.00% Rel Volume2.11 Prev Close63.43
ShortableYes LT Debt/Eq1.07 EarningsFeb 03 AMC Payout116.50% Avg Volume7.05M Price63.94
Recom2.20 SMA20-1.50% SMA50-2.42% SMA200-2.12% Volume14,648,720 Change0.80%
Jan-21-20Downgrade Guggenheim Buy → Neutral
Dec-13-19Downgrade Credit Suisse Neutral → Underperform $67 → $63
Nov-12-19Initiated SunTrust Hold $70
Oct-25-19Downgrade Maxim Group Buy → Hold
Oct-17-19Resumed BofA/Merrill Neutral $70
Jul-29-19Upgrade RBC Capital Mkts Outperform → Top Pick $91
Jul-15-19Upgrade Wells Fargo Market Perform → Outperform $68 → $88
May-28-19Downgrade Goldman Neutral → Sell
May-23-19Upgrade Citigroup Neutral → Buy
May-21-19Initiated Credit Suisse Neutral $70
Apr-26-19Initiated Bernstein Outperform $82
Apr-10-19Upgrade UBS Neutral → Buy $75 → $77
Feb-12-19Downgrade Wells Fargo Outperform → Market Perform $95 → $68
Feb-12-19Downgrade Citigroup Buy → Neutral $100 → $75
Jan-03-19Upgrade Oppenheimer Perform → Outperform $85
Oct-26-18Reiterated Barclays Overweight $90 → $95
Oct-26-18Downgrade Piper Jaffray Overweight → Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $87
Jul-26-18Downgrade Robert W. Baird Outperform → Neutral $79
Jun-28-18Initiated Raymond James Strong Buy
Jan-23-20 04:32PM  US STOCKS-S&P 500 gains, Nasdaq hits new high as investors eye earnings, coronavirus Reuters
02:29PM  US STOCKS-Wall Street pares losses on positive coronavirus news Reuters
01:54PM  Gilead assessing Ebola drug as possible coronavirus treatment Reuters
09:21AM  The one value strategy that wasnt a disaster now favors commodity sector over techs MarketWatch
Jan-22-20 05:50PM  Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know Zacks
12:16PM  High-Yield Stocks for the Dividend Investor
Jan-21-20 05:30PM  Gilead Sciences to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 4, 2020 Business Wire
Jan-19-20 03:15PM  Stocks That Fell to 3-Year Lows in the Week of Jan. 17
Jan-17-20 04:25PM  Why This Biotech's Next Chapter Is 'TBD' Amid Deal-Making Dearth Investor's Business Daily
11:40AM  GILD or EXEL: Which Is the Better Value Stock Right Now? Zacks
07:47AM  Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction Zacks
Jan-15-20 02:38PM  Parnassus Endeavor Fund Adds to Cisco, Alphabet
11:45AM  Parnassus Endeavor Fund Invests in Insurance and Logistics in 4th Quarter
10:27AM  Nektar's Pain Drug Gets Adverse Advisory Committee Decision Zacks
Jan-14-20 01:04PM  Gilead Sciences, Inc. -- Moody's announces completion of a periodic review of ratings of Gilead Sciences, Inc. Moody's
12:17PM  Performance Review of Our Annual Stock Picks
08:13AM  Should You Be Concerned About Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE? Simply Wall St.
Jan-13-20 05:50PM  Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know Zacks
09:52AM  In deal with Gilead, stealthy East Bay startup turns cell therapy against autoimmune diseases American City Business Journals
09:35AM  The Zacks Analyst Blog Highlights: Chevron, Accenture, Adobe Systems, Gilead Sciences and Honda Motor Zacks
05:45AM  Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences PR Newswire
Jan-10-20 12:37PM  Stock Research Reports for Chevron, Accenture, Adobe & Others Zacks
12:08PM  7 Healthcare Stocks to Buy or Sell As Pricing Pressures Mount InvestorPlace
Jan-09-20 05:10PM  Gilead (GILD) Inks License Deal with Xencor for HIV Candidate Zacks
09:48AM  Agenus Initiates Phase I Study on Oncology Candidate AGEN1223 Zacks
09:20AM  4 Things to Pay Attention to at the J.P. Morgan Health-Care Conference Next Week
08:30AM  Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University Business Wire
Jan-08-20 09:00AM  Gilead Stock Is Among The Biggest Biotech Stocks But Should You Buy It? Investor's Business Daily
Jan-07-20 05:50PM  Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know Zacks
Jan-06-20 10:13AM  Fear and loathing in Union Square: Upcoming biotech conference exposes industry dreams, issues American City Business Journals
Jan-03-20 05:43PM  2020 Preview: The year ahead in Bay Area biotech and health American City Business Journals
Jan-02-20 05:01PM  Novo Nordisk's Shares Up in a Year on Pipeline Progress Zacks
10:08AM  Drug-Price Increases Show Business as Usual Despite Public Pressure
08:41AM  Bristol-Myers, Gilead, Biogen, Other Drugmakers Increased U.S. List Prices on Jan. 1: Report
Jan-01-20 11:47AM  More drugmakers hike U.S. prices as new year begins Reuters
11:40AM  GILD vs. TECH: Which Stock Should Value Investors Buy Now? Zacks
11:20AM  More drugmakers hike U.S. prices as new year begins Reuters
Dec-31-19 12:01PM  Vascepas Future Looks Rosy, But It Could Still Be Fishy for Amarin Stock InvestorPlace
Dec-29-19 12:04PM  2019 Review: Most Favored Hedge Fund Stocks vs. Gilead Sciences, Inc. (GILD) Insider Monkey
Dec-27-19 10:42AM  Roche and Gilead Losing Patent Protection on Top Sellers
09:04AM  Spring Bank (SBPH) Stops Dosing in HBV Studies, Stock Down Zacks
Dec-26-19 10:26AM  Gilead (GILD) Partners With Eisai for RA Candidate in Japan Zacks
05:00AM  Pharma Companies Are Rushing to Treat a Little-Known Liver Disease. Investors Should Be Skeptical.
Dec-24-19 05:45PM  Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know Zacks
01:00AM  Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval Business Wire
Dec-23-19 09:40AM  GlaxoSmithKline's Long-Acting HIV Regimen Gets CRL From FDA Zacks
08:01AM  Gilead Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 Business Wire
Dec-20-19 08:30AM  China National Medical Products Administration Approves Vosevi® (Sofosbuvir, Velpatasvir and Voxilaprevir) for People With Chronic Hepatitis C Infection Who Require Re-Treatment Business Wire
08:27AM  Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib Zacks
08:12AM  The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering Benzinga
Dec-19-19 04:30PM  Gilead Submits Filgotinib New Drug Application to U.S. Food and Drug Administration Under Priority Review for Rheumatoid Arthritis Treatment Business Wire
10:18AM  Biotech Stock Outlook: M&A Activity Retains Growth Streak Zacks
10:13AM  The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals Zacks
Dec-18-19 02:27PM  Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More Zacks
Dec-17-19 11:13AM  Gilead's Second CAR-T Treatment Suffers the Same Issues as Yescarta
10:31AM  Gilead (GILD) Announces Top-Line Results From NASH Study Zacks
Dec-16-19 05:50PM  Gilead Sciences (GILD) Gains But Lags Market: What You Should Know Zacks
01:38PM  Amarins Vascepa Approval Seems Fishy for Patients and AMRN Investors InvestorPlace
08:00AM  Gilead Announces Topline Results From Phase 2 ATLAS Study in Patients With Bridging Fibrosis (F3) and Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) Business Wire
Dec-13-19 03:12PM  Bristol-Myers wins $752 million in U.S. patent case against Gilead Reuters
10:29AM  Biotech Stocks Are Poised to Rise in 2020, Analyst Says. Here Is His Top Pick.
Dec-12-19 09:59AM  Gilead Teams Up With Kiniksa, Submits BLA for CAR T Therapy Zacks
07:38AM  The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win Benzinga
Dec-11-19 04:05PM  Kite Submits Biologics License Application to U.S. Food and Drug Administration for Companys Second CAR T Cell Therapy Business Wire
09:41AM  Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar Zacks
08:30AM  Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma GlobeNewswire
07:04AM  The Zacks Analyst Blog Highlights: Toyota, CVS, 3M, Gilead and Goldman Zacks
05:00AM  Buckingham's Value Picks in Healthcare MoneyShow
Dec-10-19 05:45PM  Gilead Sciences (GILD) Gains As Market Dips: What You Should Know Zacks
04:31PM  Investors shift attention to next generation of CAR-T, new sickle cell treatments at major hematology meeting MarketWatch
04:00PM  Chinas Curing Cancer Faster and Cheaper Than Anywhere Else Bloomberg
03:36PM  Genfit Hopes to Buck the Odds With NASH Drug
02:27PM  Top Stock Reports for Toyota, CVS Health & 3M Zacks
09:48AM  Fate (FATE) Announces Encouraging Data on Immunotherapies Zacks
Dec-09-19 02:45PM  Kite Presents Positive Results From Pivotal ZUMA-2 Trial in Relapsed or Refractory Mantle Cell Lymphoma Business Wire
02:45PM  Kite and the CIBMTR® Present Positive Findings From Real-World Use of Yescarta® (Axicabtagene Ciloleucel) in Relapsed or Refractory Large B-Cell Lymphoma Business Wire
09:52AM  Gilead (GILD) Announces Positive Long-Term Data on Yescarta Zacks
09:36AM  Three Things You Should Check Before Buying Gilead Sciences, Inc. (NASDAQ:GILD) For Its Dividend Simply Wall St.
Dec-07-19 02:00PM  Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment Business Wire
02:00PM  Half of lymphoma patients alive three years after Gilead cell therapy treatment -study Reuters
Dec-06-19 08:32AM  Glaxo Files NDA for Fostemsavir for Heavily Pre-Treated HIV Zacks
07:36AM  Swiss approve insurance cover for Novartis, Gilead cell therapies Reuters
Dec-05-19 05:28PM  Peninsula company lands expert to marry data with drug discovery American City Business Journals
Dec-04-19 05:52PM  Bayer and Teva Double Down on Worst M&A Deals of Decade
05:00AM  Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018 American City Business Journals
Dec-02-19 11:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
09:04AM  Intercept (ICPT) Gains 7.5% YTD on Progress in NASH Space Zacks
Nov-30-19 05:44PM  Here is What Hedge Funds Think About Gilead Sciences, Inc. (GILD) Insider Monkey
Nov-29-19 08:48AM  China Negotiates Bargain Prices With Big Pharma
Nov-27-19 02:16PM  National AIDS Memorial Receives $2.4 Million Donation From Gilead Sciences to Support the AIDS Memorial Quilt as It Moves Home to San Francisco Business Wire
Nov-26-19 08:24AM  Intercept's (ICPT) NDA for NASH Drug Gets Priority Review Zacks
Nov-25-19 04:11PM  5 Top Stock Trades for Tuesday: NVDA, TSLA, GILD InvestorPlace
Nov-24-19 10:44PM  Here is the 19th Most Popular Stock Among 752 Hedge Funds Insider Monkey
Nov-22-19 08:36AM  AstraZeneca Gets FDA Nod for Calquence Line Extension in CLL Zacks
Nov-21-19 09:06PM  FirstFT: Todays top stories Financial Times
09:40AM  Biotech ETF (BBH) Hits New 52-Week High Zacks
08:30AM  Industry Veterans Appointed to Head the Global Technical Operations and Clinical Development Organizations at Kite Business Wire
Nov-19-19 10:33AM  Drug Legislation Likely to Dry Up Biotech Funding
12:00AM  Our Ultimate Stock-Pickers' Top 10 High-Conviction and New-Money Purchases Morningstar
Nov-13-19 03:43PM  Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates Zacks
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Scholar Rock Holding Corporation; Tango Therapeutics; National Cancer Institute; Pfizer, Inc.; Sangamo Therapeutics, Inc.; Gadeta B.V.; HiFiBiO Therapeutics; Agenus Inc.; HOOKIPA Pharma Inc.; Goldfinch Bio, Inc.; insitro Inc.; Nurix Therapeutics, Inc.; Lyndra Therapeutics; Carna Biosciences Inc.; and Glympse Bio, Inc., as well as the Chengdu Hi-tech Zone. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pletcher Brett AEVP,Corp Affairs & Gen CounselJan 03Option Exercise24.302,95071,67020,014Jan 06 07:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselJan 03Sale64.632,950190,65917,064Jan 06 07:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselDec 03Option Exercise24.305,900143,34122,964Dec 04 07:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselDec 03Sale65.775,900388,04317,064Dec 04 07:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 25Option Exercise40.5615,000608,40032,064Nov 26 02:14 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 25Sale66.8515,0001,002,80917,064Nov 26 02:14 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 19Option Exercise24.3010,000242,95027,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 19Sale64.9110,000649,06217,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 18Option Exercise24.3010,000242,95027,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 18Sale63.8510,000638,50017,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 05Sale66.062,095138,40417,826Nov 07 08:04 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 01Option Exercise16.892,40040,53623,921Nov 05 08:21 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 01Sale64.524,000258,09919,921Nov 05 08:21 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecOct 28Sale63.315,677359,41221,521Oct 30 08:35 PM
Lofton Kevin EDirectorOct 01Option Exercise0.0021,527064,859Oct 03 09:03 PM
WOLD OLSEN PERDirectorAug 28Option Exercise23.764,908116,590102,762Aug 29 04:42 PM
WOLD OLSEN PERDirectorAug 28Sale63.914,908313,67197,854Aug 29 04:42 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecAug 19Sale64.3560839,12327,198Aug 20 03:13 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecJul 23Option Exercise24.917,200179,31634,398Jul 25 06:37 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecJul 23Sale65.077,200468,50427,198Jul 25 06:37 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecJun 18Sale68.755,816399,85027,198Jun 20 04:52 PM
Cogan John FrancisDirectorMay 01Option Exercise22.022,86863,13957,728May 02 06:45 PM
Whitley Richard JamesDirectorMay 01Option Exercise22.029,534209,89134,669May 02 06:48 PM
Whitley Richard JamesDirectorMay 01Sale65.029,534619,93425,135May 02 06:48 PM
Cogan John FrancisDirectorMay 01Sale64.892,868186,11654,860May 02 06:45 PM
Cogan John FrancisDirectorApr 24Option Exercise22.022,70059,44157,560Apr 25 06:48 PM
Lofton Kevin EDirectorApr 24Option Exercise24.9113,208328,94543,332Apr 25 06:51 PM
Cogan John FrancisDirectorApr 24Sale62.612,700169,05454,860Apr 25 06:48 PM
Cogan John FrancisDirectorApr 17Option Exercise22.022,70059,44157,560Apr 18 07:04 PM
Cogan John FrancisDirectorApr 17Sale64.232,700173,42454,860Apr 18 07:04 PM
Cogan John FrancisDirectorApr 10Option Exercise22.022,70059,44157,560Apr 12 06:28 PM
Cogan John FrancisDirectorApr 10Sale67.232,700181,52154,860Apr 12 06:28 PM
Cogan John FrancisDirectorApr 03Option Exercise22.022,70059,44157,560Apr 04 07:31 PM
Cogan John FrancisDirectorApr 03Sale66.742,700180,19854,860Apr 04 07:31 PM
Whitley Richard JamesDirectorApr 01Option Exercise22.029,534209,89134,669Apr 02 08:10 PM
Whitley Richard JamesDirectorApr 01Sale65.489,534624,25525,135Apr 02 08:10 PM
Cogan John FrancisDirectorMar 27Option Exercise22.022,70059,44157,560Mar 28 06:09 PM
Cogan John FrancisDirectorMar 27Sale64.142,700173,17854,860Mar 28 06:09 PM
Cogan John FrancisDirectorMar 20Option Exercise22.022,70059,44157,560Mar 21 07:08 PM
Cogan John FrancisDirectorMar 20Sale65.072,700175,68954,860Mar 21 07:08 PM
WILSON GAYLE EDirectorFeb 19Option Exercise0.0019,0680143,567Feb 20 08:06 PM
WILSON GAYLE EDirectorFeb 19Sale67.0819,0681,279,074124,499Feb 20 08:06 PM